New England Journal of Medicine· 2017Q1· Clinical trial
Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer
- 5,313citations
- Q1SCImago
- 2017year
Short summary
In previously untreated patients with EGFR-mutated advanced non-small-cell lung cancer, osimertinib significantly extended progression-free survival by nearly double (18.9 vs. 10.2 months) compared to standard EGFR-TKIs.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Pulmonary and Respiratory Medicine
Pulmonary and Respiratory MedicineMedicine